Treatment of Clostridium difficile colitis in hamsters with a lipopeptide antibiotic, LY146032 | Zendy

M. Y. Dong | Zendy; T.-W. Chang | Zendy; S. L. Gorbach | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of Clostridium difficile colitis in hamsters with a lipopeptide antibiotic, LY146032

Author(s) -

M. Y. Dong,

T.-W. Chang,

S. L. Gorbach

Publication year - 1987

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.31.7.1135

Subject(s) - pseudomembranous colitis , clostridium difficile , lipopeptide , antibiotics , microbiology and biotechnology , hamster , peptidoglycan , colitis , vancomycin , antibacterial agent , clostridium , biology , medicine , bacteria , immunology , staphylococcus aureus , genetics

LY146032, an acidic lipopeptide antibiotic which inhibits the biosynthesis of cell wall peptidoglycan, was found to be effective in delaying death in a hamster model of pseudomembranous colitis. A dose of 0.05 mg/day was effective. The equivalent protection with vancomycin required a dose 100-fold higher, i.e., 5 mg/day.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research